



Supplemental Figure 1: Schematic outline of HCV+ LT patients included in the study.

Supplemental Table 1: HCV Treatment Regimens

Genotype, N (%)	DAA Pre-Transplant (N=17)	DAA Post-Transplant (N=23)	Patients without SVR Post-Transplant (N=8)
1			
Sofosbuvir/Ledipasvir	12 (70.6)	14 (60.9)**	4 1-failed Sofosbuvir/Ledipasvir 1-death on treatment with FCH 1-death on treatment with ductopenic rejection 1-untreated
Sofosbuvir/Ribavirin	1 (5.9)*	3 (13.0)	
Sofosbuvir/Simeprevir	1 (5.9)	2 (8.7)	
2			
Sofosbuvir/Ribavirin	1 (5.9)	0	0
Sofosbuvir/Ledipasvir	0	1 (4.3)	
3			
Sofosbuvir/Ribavirin	1 (5.9)	0	4 3-untreated 1-death with FCH
Sofosbuvir/Ledipasvir	0	1 (4.3)	
Study Protocol	0	1 (4.3)***	
4			
Sofosbuvir	1 (5.9)	0	0

*N=1 Failed to achieve SVR; **N=2 Failed to achieve SVR; ***Presently on treatment.
FCH (Fibrosing Cholestatic Hepatitis)